Loading organizations...
§ Private Profile · San Carlos, CA, USA
Biopharmaceutical company that developed antibody-based immunotherapies for cancer, now undergoing wind-down and liquidation.
Atreca is a San Carlos, California-based biopharmaceutical company that discovers and develops novel antibody-based immunotherapies for oncology applications using its proprietary Immune Repertoire Capture platform. Before initiating a formal liquidation process in early 2024, the enterprise historically employed over 100 staff members and secured more than $200 million in private financing prior to a $125 million initial public offering in 2019. The firm received financial backing from notable institutional investors including Cormorant Asset Management and Wellington Management, while also establishing strategic licensing agreements with the Bill & Melinda Gates Medical Research Institute. Following clinical setbacks with its lead oncology candidate, the organization executed multiple 40 percent workforce reductions in 2023 and subsequently divested a portfolio of preclinical antibodies to Immunome for $5.5 million. Atreca was founded in 2010 by Tito Serafini, William Robinson, and Lawrence Steinman.
Atreca has raised $222.0M across 4 funding rounds.
Atreca has raised $222.0M in total across 4 funding rounds.
Atreca has raised $222.0M across 4 funding rounds. Most recently, it raised $125.0M Series C in September 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 12, 2018 | $125M Series C | — | Aisling Capital, Boxer Capital, Cormorant Asset Management, EcoR1 Capital, Redmile Group, Samsara BioCapital, Tekla Capital Management, Wellington Management | Announced |
| Aug 17, 2017 | $35M Series B | Wellington Management | Cormorant Asset Management | Announced |
| Nov 4, 2015 | $56M Series A | — | Trevor Mundel, GlaxoSmithKline, Mission BAY Capital | Announced |
| Sep 25, 2012 | $6M Venture Round | Bill & Melinda Gates Foundation | — | Announced |
Atreca has raised $222.0M in total across 4 funding rounds.
Atreca's investors include Aisling Capital, Boxer Capital, Cormorant Asset Management, EcoR1 Capital, Redmile Group, Samsara BioCapital, Tekla Capital Management, Wellington Management, Trevor Mundel, GlaxoSmithKline, Mission Bay Capital, Bill & Melinda Gates Foundation.